Secondary Logo

Journal Logo

Evolution of Bordetella pertussis

He, Qiushui MD, PhD

The Pediatric Infectious Disease Journal: August 2016 - Volume 35 - Issue 8 - p 915–917
doi: 10.1097/INF.0000000000001218
ESPID Reports and Reviews
Free

From the *Department of Medical Microbiology and Research Centre of Microbiome, Capital Medical University, Beijing, China; and Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland.

The authors has no conflicts of interest to disclose.

Address for correspondence: Qiushui He, MD, PhD, Department of Medical Microbiology and Immunology, University of Turku, Kiinamyllynkatu 13, 20520 Turku, Finland. E-mail: Qiushui.He@utu.fi.

Bordetella pertussis, a Gram-negative bacterium, causes whooping cough (pertussis) in humans. Vaccination against pertussis was first introduced in the 1950s. The coverage of primary vaccination has been high in industrialized countries where acellular vaccines (ACVs) are commonly used. In many developing countries, the vaccination coverage is increasing and whole-cell vaccines (WCVs) are mainly in use. WCVs include inactivated whole bacteria, whereas ACVs comprise purified antigens including pertussis toxin (Ptx), filamentous hemagglutinin, pertactin (Prn), fimbriae (Fim) 2 and Fim3 in different combinations and concentrations. Compared with WCVs, ACVs are less reactogenic and are also used for booster vaccinations in older children and adults. Despite extensive vaccinations, pertussis has resurged in industrialized countries since the beginning of the 21st century.1–3 Major explanations for the resurgence are waning immunity associated with ACVs and bacterial adaptation to vaccine-induced immunity. Compared with the vaccine strains, continuous changes have been observed in genomes of B. pertussis circulating in immunized populations. Common methods used for surveillance of B. pertussis isolates include serotyping, genotyping for vaccine antigens and genomic analyses by multilocus variable number of tandem repeat analysis (MLVA) and pulsed-field gel electrophoresis (PFGE).4 More recently, whole genome sequencing has been applied.5,6 Many studies demonstrate that variation of B. pertussis occurs in both phenotypes and genotypes.

Back to Top | Article Outline

CHARACTERISTICS OF B. pertussis IN INDUSTRIALIZED COUNTRIES WHERE WCVS HAVE BEEN REPLACED BY ACVs

B. pertussis produces 3 serotypes: Fim2, Fim3 or Fim2 and 3. Fim2 isolates predominate in unvaccinated populations, whereas they are largely displaced by Fim3 strains, when vaccination is introduced with WCVs containing both Fim2 and Fim3. Today, isolates with Fim3 predominate in most countries. In Finland, ACV has been used since 2005, and the ACV does not contain purified Fim2/3 antigens. The frequency of Fim3 was about 50% in 2005, increased to 100% in 2007 and peaked until 2009. In 2013 to 2015, frequencies of Fim3 and Fim2 isolates were 20% and 80%, respectively. It remains to be demonstrated what were the determinants of these changes, that is, natural infection, vaccination or both.

B. pertussis variation with respect to Ptx and Prn was first reported in 1998 in the Netherlands, where WCV has been used for more than 40 years. Polymorphisms in Ptx are caused by point mutation and are mostly found in the enzymatic subunit S1 (ptxA). So far, 8 alleles (ptxA1 to ptxA8) have been reported. Of them, 5 (ptxA1, ptxA2, ptxA4, ptxA5 and ptxA8) code for polymorphic proteins and the other 3 produce the same protein as ptxA1. Thirteen prn alleles have been described, and these polymorphisms are mainly caused by insertions or deletions of the repeating unit of 5 amino acids GGXXP. Almost all vaccine strains used for production of WCVs and ACVs carry ptxA2 or ptxA4 and prn1 or prn7, whereas the circulating isolates harbor ptxA1 and prn2 or prn3 (Table 1).

TABLE 1

TABLE 1

Polymorphisms in the promoter region of the Ptx gene arise from point mutations. Currently, 17 ptxP alleles have been documented, and in the prevaccine era, isolates with the ptxP1 and ptxP2 alleles predominated. After the introduction of vaccination, mainly ptxP1 alleles were detected. The vaccine strains also harbor ptxP1. Although isolates with ptxP3 were first detected in the late 1980s,1 their rapid expansion in many industrial countries started in the late 1990s at a time when ACVs were being introduced. Today, the ptxP3 isolates are common in Europe, Australia and the United States (Table 1). The point mutation in ptxP3 isolates occurs in a binding site for the transcriptional regulator of B. pertussis and therefore it could increase the binding affinity of the transcriptional regulator and result in increased production of Ptx protein. Indeed, the ptxP3 isolates tested appeared to produce more Ptx than ptxP1 strains.1 The emergence of ptxP3 strains was also found to be associated with resurgence of pertussis in Australia and the Netherlands.

The allele profiles of vaccine strains are mainly ptxA2/prn1/ptxP1. However, the current isolates circulating in the United States, Australia and most European countries contain ptxA1/prn2/ptxP3 (Table 1). For ptxA, the change to nonvaccine types occurred in 1960 to 1980, for prn in 1980 to 1990 and for ptxP in 1990 to 2000. It should be kept in mind that in industrial countries, vaccinations with WCVs were started more than 50 years ago, and the switch from WCVs to ACVs took place in last 10 to 20 years. Furthermore, in these countries, the vaccination coverage has been generally high.

About 300 distinct MLVA types have been reported (http://www.mlva.net/), and currently, the predominant type is MT27 in the United States, Australia and most of European countries. A linkage between ptxP3 and MT27 has been documented, and almost all ptxP3 isolates had MLVA type MT27.4

For genomic typing of B. pertussis, PFGE technique has high resolution compared with MLVA. By using PFGE, the EUpertstrain group has recently compared 396 clinical isolates collected in 3 periods: 1998 to 2001 (N = 102), 2004 to 2005 (N = 154) and 2007 to 2009 (N = 140) from 9 countries including Denmark, Finland, France, Germany, the Netherlands, Norway, Poland, Sweden and the United Kingdom.4 Altogether, 81 distinct profiles were identified, 5 of which (BpSR3, BpSR5, BpSR10, BpSR11 and BpSR12) were found in over 60% of the testing isolates and shown to be predominant in all countries except Poland. Although emergence of new PFGE profiles was not detected, frequencies of the 5 common profiles varied during the 3 study periods. For example, there was a decrease in frequency of BpSR11 and increase in frequency of BpSR3 and BpSR10 with time.

Whole genome sequencing has proven to be most informative for surveillance of bacterial pathogens. Recently, a comparative study based on a global collection of 343 clinical isolates revealed that the worldwide B. pertussis population underwent major changes during last 60 years.5 The phylogeographic analyses of these isolates suggest that adaptive evolution of this pathogen is closely associated with the introduction of vaccines. When complete genomes of 40 clinical isolates from Finland (high vaccination coverage) and China (relatively low coverage) were compared, the study revealed that the molecular clock moved at different rates in the 2 countries and in distinct periods, further showing that evolution of B. pertussis was closely associated with the country vaccination coverage.6

Very recently, B. pertussis not producing Prn has been increasingly isolated in countries experiencing epidemics of pertussis.2,3 During the outbreak in Washington, United States, in 2012, over 60% of isolates did not produce Prn (Table 1).2 Even higher frequency of Prn-negative isolates was observed in Australia during the epidemic period of 2008 to 2012.3 The Prn-deficient isolates were first detected in France in 2003.7 However, no dramatic rise was found in this country, and in 2013, its frequency was around 15%. Although Prn-deficient isolates were also reported in other European countries such as Finland, the Netherlands, Norway and Sweden, their frequencies were generally low (Table 1).8 Several mechanisms such as gene deletion, internal stop codon created by mutation and promoter inversion can cause Prn deficiency. However, the most common one is due to the mutation mediated by IS481 insertion. Interestingly, Prn deficiency was not observed among the global collection of 343 isolates predominantly from 2008 or earlier.5 It is generally believed that emergence of Prn-deficient isolates is driven by ACVs. Notably, the United States and Australia are 2 of the countries in the world where ACVs were first used for primary vaccinations. In Europe, Sweden and Italy started with ACVs for primary vaccinations in the mid-1990s. However, the vaccination strategies in the 2 countries differ from the United States and Australia. In Sweden, vaccination with WCVs was stopped between 1979 and 1995, whereas in Italy, the vaccination coverage of WCVs was quite low before the 1990s. Therefore, it seems that the immunity and the extent of selective pressure induced by ACVs in whole populations in Sweden and Italy may differ from those in the United States and Australia where the pertussis vaccinations have been continuously used and the coverage has been high. As ACVs have now been used in Sweden and Italy for almost 20 years, it will be determined whether there will be an emergence of Prn-deficient isolates in these countries.

The emergence of Prn-deficient isolates raises questions about its role in pertussis. An analysis of clinical symptoms caused by Prn-positive and Prn-negative isolates in French infants did not show major differences between the 2 groups, suggesting that the lack of Prn does not seem to affect bacterial virulence or transmission.7 When a large number of patients from whom Prn-positive and Prn-negative strains were isolated were compared in the United States, a significant association between vaccination and Prn status was found, suggesting that vaccinated persons have greater susceptibility to be infected by Prn-negative strains compared with Prn-positive ones.3 Another important question that needs to be addressed is the impact of Prn-deficient isolates on effectiveness/efficacy of ACVs. Further, it remains to be shown whether there will be emergence of Ptx- or filamentous hemagglutinin-deficient isolates in ACV-immunized populations since the 2 antigens are also included in ACVs.

Back to Top | Article Outline

CHARACTERISTICS OF B. pertussis IN COUNTRIES WHERE WCVs HAVE BEEN CONTINUOUSLY USED

Our current knowledge about B. pertussis evolution is mostly obtained from industrial countries where ACVs have been used. To better understand bacterial adaptation to ACV-induced selection pressure, we need to look at B. pertussis circulating in countries where WCVs have been continuously used. Poland is 1 European country in which WCV is still in use for primary vaccination. In Poland, the currently dominant allele profiles are ptxA1/prn1/ptxP1 and ptxA1/prn2/ptxP1 (Table 1).4 The difference in allele profiles observed between Poland and most European countries was also confirmed by genomic analyses of PFGE and MLVA. In China, WCVs have been continuously used since 1960s. About 100 isolates collected during 2013 to 2014 from several different regions of this country were studied, and the prevalent allele profile was found to be ptxA1/prn1/ptxP1 (Table 1).9 Furthermore, the common MLVA type and PFGE profiles identified in Europe were seldom detected in China.10 These findings from Poland and China indicate that B. pertussis circulating in countries where WCVs have been continuously used differ from those in industrialized countries where ACVs have been in use since 1990s, suggesting that ACVs induce accelerated selection pressure for bacterial population compared with WCVs.

Back to Top | Article Outline

CONCLUSIONS

Evolution of B. pertussis after the start of vaccination occurs toward nonvaccine-type strains, although the timing and speed of changes in bacterial populations may differ in different countries. Bacterial adaptation to vaccine-induced immunity started with alteration in the structural genes coding for vaccine antigens and was followed by functional changes with respect to production of vaccine antigens such as Prn. Ongoing surveillance of B. pertussis populations and evaluation of the impact of these changes on effectiveness of vaccines and disease incidence are critical to inform the optimal vaccination programs to prevent pertussis.

Back to Top | Article Outline

REFERENCES

1. Mooi FR, van Loo IH, van Gent M, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15:1206–1213.
2. Lam C, Octavia S, Ricafort L, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis. 2014;20:626–633.
3. Martin SW, Pawloski L, Williams M, et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60:223–227.
4. van Gent M, Heuvelman KJ, van der Heide HGJ, et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries from 1998–2012. Eur J Clin Microbiol Infect Dis. 2015;34:821–830.
5. Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio. 2014;5:e01074.
6. Xu Y, Liu B, Gröndahl-Yli-Hannuksila K, et al. Whole-genome sequencing reveals the effect of vaccination on the evolution of Bordetella pertussis. Sci Rep. 2015;5:12888.
7. Bodilis H, Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis. 2013;19:471–474.
8. Zeddeman A, van Gent M, Heuvelman K, et al. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012. Euro Surveill. 2014;19: 20881.
9. Yang Y, Yao K, Ma X, et al. Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970–2014). PLoS One. 2015;10:e0138941.
10. Wang Z, He Q. Bordetella pertussis isolates circulating in China where whole cell vaccines have been used for 50 years. Clin Infect Dis. 2015;61:1028–1029.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.